Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 9/20 | 0.69 |
| ▸ | JAK1 | P23458 | 9/20 | 0.69 |
| ▸ | TTK | P33981 | 3/20 | 0.69 |
| ▸ | TYK2 | P29597 | 2/20 | 0.69 |
| ▸ | JAK3 | P52333 | 13/20 | 0.60 |
| ▸ | AURKA | O14965 | 1/20 | 0.59 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.55 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15546548 | 0.92 | JAK2 (0.69) | JAK2JAK1TTKTYK2JAK3 | |
| SCHEMBL15545983 | 0.90 | JAK2 (0.69) | JAK2JAK1TTKTYK2JAK3 | |
| SCHEMBL15560976 | 0.89 | JAK3 (0.58) | JAK2JAK1TTKTYK2JAK3 | |
| SCHEMBL15560708 | 0.88 | JAK3 (0.59) | JAK2JAK1TTKTYK2JAK3 | |
| SCHEMBL15546652 | 0.88 | JAK2 (0.66) | JAK2JAK1TTKTYK2JAK3 | |
| SCHEMBL15546184 | 0.87 | NTRK1 (0.56) | JAK2JAK1TTKTYK2JAK3 | |
| SCHEMBL15560326 | 0.86 | JAK2 (0.74) | JAK2JAK1TTKTYK2JAK3 | |
| SCHEMBL20204910 | 0.85 | JAK2 (0.72) | JAK2JAK1TTKTYK2JAK3 | |
| SCHEMBL15560984 | 0.85 | JAK3 (0.56) | JAK2JAK1TTKTYK2JAK3 | |
| SCHEMBL23082062 | 0.85 | JAK1 (0.82) | JAK2JAK1TTKTYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2855451-B1 | HETEROCYCLYL PYRIMIDINE ANALOGUES AS TYK2 INHIBITORS | CELLZOME LTD (GB) | 2017-10-04 | — | — | EP | claimed |
| US-9655897-B2 | Heterocyclyl pyrimidine analogues as TYK2 inhibitors | CELLZOME LIMITED (GB) | 2017-05-23 | — | — | US | claimed |
| US-20160184307-A1 | Heterocyclyl Pyrimidine Analogues As TYK2 Inhibitors | CELLZOME LIMITED (GB) | 2016-06-30 | — | — | US | claimed |
| US-9296725-B2 | Heterocyclyl pyrimidine analogues as TYK2 inhibitors | CELLZOME LIMITED (GB) | 2016-03-29 | — | — | US | claimed |
| US-20150166513-A1 | Heterocyclyl Pyrimidine Analogues As TYK2 Inhibitors | CELLZOME LIMITED (GB) | 2015-06-18 | — | — | US | claimed |
| EP-2855451-B1 | HETEROCYCLYL PYRIMIDINE ANALOGUES AS TYK2 INHIBITORS | CELLZOME LTD (GB) | 2017-10-04 | — | — | EP | disclosed |
| EP-2855451-B1 | HETEROCYCLYL PYRIMIDINE ANALOGUES AS TYK2 INHIBITORS | CELLZOME LTD (GB) | 2017-10-04 | — | — | EP | disclosed |
| US-9655897-B2 | Heterocyclyl pyrimidine analogues as TYK2 inhibitors | CELLZOME LIMITED (GB) | 2017-05-23 | — | — | US | disclosed |
| US-9655897-B2 | Heterocyclyl pyrimidine analogues as TYK2 inhibitors | CELLZOME LIMITED (GB) | 2017-05-23 | — | — | US | disclosed |
| US-9655897-B2 | Heterocyclyl pyrimidine analogues as TYK2 inhibitors | CELLZOME LIMITED (GB) | 2017-05-23 | — | — | US | disclosed |
| US-20160184307-A1 | Heterocyclyl Pyrimidine Analogues As TYK2 Inhibitors | CELLZOME LIMITED (GB) | 2016-06-30 | — | — | US | disclosed |
| US-20160184307-A1 | Heterocyclyl Pyrimidine Analogues As TYK2 Inhibitors | CELLZOME LIMITED (GB) | 2016-06-30 | — | — | US | disclosed |
| US-9296725-B2 | Heterocyclyl pyrimidine analogues as TYK2 inhibitors | CELLZOME LIMITED (GB) | 2016-03-29 | — | — | US | disclosed |
| US-9296725-B2 | Heterocyclyl pyrimidine analogues as TYK2 inhibitors | CELLZOME LIMITED (GB) | 2016-03-29 | — | — | US | disclosed |
| US-9296725-B2 | Heterocyclyl pyrimidine analogues as TYK2 inhibitors | CELLZOME LIMITED (GB) | 2016-03-29 | — | — | US | disclosed |
| US-20150166513-A1 | Heterocyclyl Pyrimidine Analogues As TYK2 Inhibitors | CELLZOME LIMITED (GB) | 2015-06-18 | — | — | US | disclosed |
| US-20150166513-A1 | Heterocyclyl Pyrimidine Analogues As TYK2 Inhibitors | CELLZOME LIMITED (GB) | 2015-06-18 | — | — | US | disclosed |
| US-20150166513-A1 | Heterocyclyl Pyrimidine Analogues As TYK2 Inhibitors | CELLZOME LIMITED (GB) | 2015-06-18 | — | — | US | disclosed |
| EP-2855451-A1 | HETEROCYCLYL PYRIMIDINE ANALOGUES AS TYK2 INHIBITORS | Cellzome Limited (GB) | 2015-04-08 | — | — | EP | disclosed |
| WO-2013174895-A1 | HETEROCYCLYL PYRIMIDINE ANALOGUES AS TYK2 INHIBITORS | CELLZOME LIMITED (GB) | 2013-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166513-A1 | Heterocyclyl Pyrimidine Analogues As TYK2 Inhibitors | TYK2, TXK, IRAK1 | JAK2 10/4885JAK1 6/4885TTK 293/4885 |
| US-20160184307-A1 | Heterocyclyl Pyrimidine Analogues As TYK2 Inhibitors | TYK2, TXK, IRAK1 | JAK2 10/4885JAK1 6/4885TTK 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.